Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 6.62%, which has investors questioning if this is right time to ...

Abstract: This article explores the average controllability of composite networks generated by factor networks via Cartesian product from energy control perspective, which can be characterized by the ...

Shares of Cartesian Therapeutics climbed after the company announced positive results in a phase 2b trial of its lead cell-therapy candidate. The stock was up 8.3% to $15.60 in morning trading Tuesday ...

Cartesian Therapeutics Inc. unveiled 12-month efficacy and safety data from the phase IIb trial of Descartes-08 in participants with generalized myasthenia gravis (MG). Participants dosed with a ...

Former Y Combinator startup telli is helping companies alleviate the bottleneck that occurs when a high-volume of customers ...

The global industrial robotics market encompasses the manufacturing, deployment, and utilization of robotic systems across various industrial sectors. Industrial robotics play a crucial role in ...

Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in ...

The H-811.I2 miniature hexapod from Physik Instrumente (PI) stands out with its small footprint and its proven reliability in applications with high numbers of cycles, such as in optical manufacturing ...

US biotech Cartesian Therapeutics has reported that patients with generalized myasthenia gravis (gMG) continued to experience ...